

## REMARKS

### Interview Summary

Applicants thank the Examiner for the courtesy of the June 4, 2007 telephone interview regarding the restriction requirement. During the phone call, applicants' agent pointed out to the Examiner that the Examiner's groups in the restriction requirement did not encompass all of the claimed subject matter. The Examiner responded that the following are also included in Group I:

- Compounds of formula I wherein  $R^4$  is an optionally substituted  $C_{1-6}$ aliphatic;
- Compounds of formula I wherein  $R^4$  is  $-(U)_jCy^3$ ;
- Compounds of formula I wherein  $R^4$  is  $-(U)_jAr^3$ ; wherein  $j$  is 1

The Examiner further clarified that the following is included in Group II (under the term "aromatic" in the restriction requirement):

- Compounds of formula I wherein  $R^4$  is  $-(U)_jAr^3$ ; wherein  $j$  is 0 and  $Ar^3$  is an optionally substituted aryl group selected from a 3-8 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein  $Ar^3$  is not one of the groups already recited by the Examiner in the restriction requirement, namely "phenyl," "pyrazine, pyrimidine, or pyridazine," and "quinazoline."

### The Claim Amendments

#### Restriction Requirement

Applicants have amended claims 1, 22-25, 28, 43-44, 51 and 52 in accordance with the response to the restriction requirement. Applicants have withdrawn rather than cancelled claims 55-63 to preserve the option of rejoining these claims. Applicants reserve the right to pursue any unelected subject matter in continuing applications claiming priority herefrom.

### Voluntary Amendments

Applicants have amended claim 1 to add the variable “y” to recite the number of occurrences of Z-R<sup>y</sup>. Support for this amendment may be found in the specification as originally filed (see e.g., page 17, paragraph [0052] to page 20, paragraph [0058], disclosing the variable y, which indicates the number of occurrences of Z-R<sup>y</sup> in the compounds of formula I).

Applicants have amended claim 1 to remove the period at the end of sections “d)” “e)” and “f).”

Applicants have amended claims 22 and 23 to correct inadvertent typographical errors. Applicants have amended the definition of X as “OR<sup>4</sup>” to “O.” Applicants have also amended the definition of X as “SR<sup>4</sup>” to “S.” Support for these amendments may be found in the specification as originally filed (see e.g., the definition of X on page 10, which defines X as a valence bond, O, S, or NR).

These amendments add no new matter.

### The Restriction Requirement

The Examiner has required restriction of the claims in this application under 35 U.S.C. § 121 to one of the following eight groups:

- I. The compounds and compositions according to Claims 1 (in part), 2-23, 24-25 (in part), 26-27, 28 (in part), 29-42, 43-44 (in part), 45-50, 51-52 (in part), and 53-54 of formula I, wherein R<sup>4</sup> is H, absent, an optionally substituted C<sub>1-6</sub>aliphatic; -(U)<sub>j</sub>Cy<sup>3</sup>, wherein j is 0 or 1; or -U-Ar<sup>3</sup>.
- II. The compounds and compositions of formula I, wherein R<sup>4</sup> is aromatic or phenyl.
- III. The compounds and compositions of formula I, wherein R<sup>4</sup> is pyrazine, pyrimidine or pyridazine.
- IV. The compounds and compositions of formula I, wherein R<sup>4</sup> is quinazoline.
- V. The methods of treating according to claims 55-63, wherein R<sup>4</sup> is H, absent, an optionally substituted C<sub>1-6</sub>aliphatic; -(U)<sub>j</sub>Cy<sup>3</sup>, wherein j is 0 or 1; or -U-Ar<sup>3</sup>.

- VI. The methods of treating according to claims 55-63, wherein R<sup>4</sup> is aromatic or phenyl.
- VII. The methods of treating according to claims 55-63, wherein R<sup>4</sup> is pyrazine, pyrimidine or pyridazine.
- VIII. The methods of treating according to claims 55-63, R<sup>4</sup> is quinazoline.

Applicants elect for further prosecution, Group I (Claims 1 (in part), 2-23, 24-25 (in part), 26-27, 28 (in part), 29-42, 43-44 (in part), 45-50, 51-52 (in part), and 53-54)) drawn to the compounds and compositions according to formula I, wherein R<sup>4</sup> is H, absent, an optionally substituted C<sub>1-6</sub>aliphatic; -(U)<sub>j</sub>Cy<sup>3</sup>, wherein j is 0 or 1; or -U-Ar<sup>3</sup>.

The Examiner has also required a species election. Applicants respectfully submit that applicants have already elected a species in the April 27, 2007 response to the restriction requirement mailed on March 27, 2006. In that response, applicants elected compounds I-2 (see page 30, paragraph [0099]) without traverse.

### Conclusion

Applicants request that the Examiner enter the above amendments, consider the above remarks, and allow the pending claims to issue.

Respectfully submitted,

/Jennifer Che/  
Jennifer G. Che (Reg. No. 58,035)  
Agent for Applicants  
Lisa A. Dixon (Reg. No. 40,995)  
Attorney for Applicants  
Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617)444-6525  
Fax.: (617)444-6483  
**Customer Number: 27916**